MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.leukres.2013.05.004

Медицинская библиотека · Leukemia research · 2013

Fludarabine: a review of the clear benefits and potential harms.

Lukenbill Joshua, Kalaycio Matt

СтатьяОбзорПеревод пока не подготовлен

Аннотация

BACKGROUND

Fludarabine successfully treats chronic lymphocytic leukemia (CLL); however, its use may lead to significant myelosuppression and other toxicities. This article weighs the benefits against potential harms, highlighting strategies for appropriate patient selection and administration.

METHODS

Relevant studies were identified upon literature review, which were combined with our clinical and institutional experience.

RESULTS

Fludarabine-based regimens result in an overall response rate of approximately 95% and of untreated CLL patients. Fludarabine also causes potentially irreversible grade 3 or 4 cytopenias and infection in the majority of patients. Furthermore, future hematopoietic cell mobilization may be difficult and secondary myelodysplastic syndrome and leukemia occur in at least 3% of patients.

CONCLUSION

Fludarabine should be used judiciously in older patients, and avoided entirely in patients with renal insufficiency. Close monitoring of blood cell counts with appropriate dose reduction/omission is vital. Finally, alternatives such as pentostatin and bendamustine should be considered.

Для цитирования: Lukenbill Joshua, Kalaycio Matt. Fludarabine: a review of the clear benefits and potential harms.. Leukemia research. 2013. DOI: 10.1016/j.leukres.2013.05.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.